Viridian Therapeutics, Inc.\DE paid its 5 named executives $19.6M in total in FY2025 (Dec). CEO Stephen Mahoney was paid $6.8M of that.
Pay$100 in the stock at the end of FY21 → $157
Pay of each named executive
Stephen MahoneyChief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
| FY2025 (Dec) |
1 year
Thomas BeethamChief Operating Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
5 years
Seth HarmonChief Financial Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) |
4 years
Jennifer TousignantChief Legal Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) | ||||||
| FY2022 (Dec) | ||||||
| FY2021 (Dec) |
5 years
CEO pay against the pay peers
In FY2024 (Dec), the median CEO pay of the 7 peers with pay on file was $7.3M. CEO pay of Viridian Therapeutics, Inc.\DE for that year is not on file.
- 1Anaptysbio
- 2Celldex Therapeutics
- 3Immunovant
- 4Arcus Biosciences
- 5Keros Therapeutics
- 6Kura Oncology
- 7Arcutis Biotherapeutics
- 8Viridian Therapeutics, Inc.\DEThis companyNot disclosed
- 9Aerovate TherapeuticsNot disclosed
- 10Akero TherapeuticsNot disclosed
- 11Crinetics PharmaceuticalsNot disclosed
- 12Day One BiopharmaceuticalsNot disclosed
- 13KalVista PharmaceuticalsNot disclosed
- 14Kiniksa PharmaceuticalsNot disclosed
- 15Mersana TherapeuticsNot disclosed
- 16Morphic HoldingNot disclosed
- 17Pliant TherapeuticsNot disclosed
- 18ProthenaNot disclosed
- 19Replimune GroupNot disclosed
- 20Sutro BiopharmaNot disclosed
- 21Syndax PharmaceuticalsNot disclosed
- 22Ventyx BiosciencesNot disclosed
- 23Viking TherapeuticsNot disclosed
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.